SBIR-STTR Award

An automated digital pathology lab for rapid on-site processing and imaging of tissue biopsies
Award last edited on: 1/16/2022

Sponsored Program
STTR
Awarding Agency
NSF
Total Award Amount
$1,225,000
Award Phase
2
Solicitation Topic Code
BM
Principal Investigator
Mei Wang

Company Information

Instapath Inc (AKA: Instapath Bioptics)

5855 Marcia Avenue
New Orleans, LA 70124
   (504) 810-6152
   info@instapathbio.com
   www.instapathbio.com

Research Institution

Tulane University

Phase I

Contract Number: 1820258
Start Date: 7/1/2018    Completed: 6/30/2019
Phase I year
2018
Phase I Amount
$225,000
This STTR Phase 1 project seeks to develop an automated system that would significantly increase the speed and accuracy of biopsy assessments at the point of care. The proposed technology eliminates extensive manual tissue processing steps and generates digital images of fresh biopsies that look just like standard pathology slides. The imaging can be performed in seconds, thus improving the efficiency of biopsy assessments at the point of care. Rapid, whole fresh biopsy imaging also improves evaluation accuracy while maximally preserving tissue for further testing and facilitating remote pathology consultation. With over five million patients in the United States undergoing biopsy procedures each year, and one in five of those patients returning for repeat procedures due to inaccuracies in biopsy assessments, an increase in accuracy and procedure speed could have a profound impact. This could lead to decreases in patient procedure time and decreases in repeat procedure rates, preventing unnecessary, painful, and invasive repeat biopsy procedures. With an estimated 1.6 billion USD spend on repeat procedures per year, this would also represent a significant decrease in financial burden on patients. In addition, due to the decrease in time per procedure, this could increase procedure throughput for hospitals, thus increasing hospital revenue potential. Finally, by producing remotely viewable images, this system could be utilized in a remote pathology setting at underserved communities within the US.This STTR Phase I project seeks to develop an automated sample processing and tissue pathology imaging system that delivers biopsy-to-image in a completely automated manner on fully-intact fresh tissues within five minutes of tissue removal. Through integration with the previously developed Video-Rate Structured Illumination Microscopy (VR-SIM) system as the integrated optical sectioning modality, and using novel fluorescence dye combinations that recapitulate gold-standard histology, the throughput, efficiency, and accuracy of biopsy evaluation can be improved while maximally preserving tissue for downstream processing and readily facilitating telepathology consultation. Preliminary work in multiple fresh tissue preparations, including core-needle biopsies and whole surgical resections, indicates that the technology and method can deliver high image quality and diagnostic accuracy in short, clinically-relevant timeframes. A prototype of an automated, disposable cartridge system for biopsy staining and imaging for effortless integration with VR-SIM imaging will be developed. Image quality will be optimized at the highest optical sectioning power to be equivalent to physically-sectioned tissues, using polarization-gated VR-SIM and novel immersion media. ADPL workflow testing, validation of diagnostic image quality, and verification of compatibility with downstream analysis in human biopsy samples will be completed.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

Phase II

Contract Number: 2039417
Start Date: 3/1/2021    Completed: 2/28/2023
Phase II year
2021
Phase II Amount
$1,000,000
The broader impact/ commercial potential of this Small Business Innovation Research (SBIR) Phase II project supports digital pathology. For the past century, pathology has been performed on microscopically thin sections of tissues that are stained and mounted onto glass microscope slides for analysis by a pathologist. This process is labor-intensive, costly, and the turnaround time is typically one week. For the vast majority of biopsy procedures, the diagnostic result is not obtained for days or even weeks after the procedure. Current bedside pathology techniques for rapid diagnosis and quality assurance of biopsy samples are slow, inaccurate, destructive to the tissue, and require the presence of multiple trained personnel, which prevent them from being widely used. Recent technological advances allow digitizing of the physical microscope slides and enable a fully digital pathology workflow. However, to date no system can take a fresh tissue sample through the entire long, laborious processing lifecycle prior to imaging. This project will develop a tissue processing and imaging platform to enable fast, automated processing from the fresh sample to the digital image within minutes of tissue removal. This will provide better care and patient outcomes and enables new opportunities to provide care in clinical settings with more limited pathology resources. This Small Business Innovation Research Phase II project continues development of an integrated technology platform that automates the entire process of tissue processing and digital imaging, obviating the need for trained personnel to be on-site. This project will support the development of new strategies to automate the acquisition of high-quality microscopic images from samples with widely varying surface topographies, while simultaneously improving both speed and image quality to meet clinical needs. The new technologies will support parallel, hands-free automated sample processing to increase throughput for analysis of multiple samples in a single session. The project will culminate in verification and clinical validation of the integrated system.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.